Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF

Table 4 Significant correlations between TFPI single nucleotide polymorphisms (SNPs) and TFPI mRNA expression in breast tumors

Probe	SNP	Region	Alleles ^a	Minor allele frequency	Beta	r	P	False discovery rate
TFPIα	rs2192824^b	Intronic	C:T	0.490	−0.209	−0.180	0.029	0.200
TFPIα	rs7594359^b	Intronic	C:T	0.483	−0.219	−0.184	0.025	0.200
TFPIβ	rs3213739^b	Intronic	G:T	0.417	0.187	0.213	0.010	0.032
TFPIβ	rs8176479^b	Intronic	C:A	0.238	0.184	0.192	0.021	0.049
TFPIβ	rs2192824^b	Intronic	C:T	0.490	−0.267	−0.273	0.001	0.011
TFPIβ	rs12613071^b	Intronic	T:C	0.158	0.284	0.208	0.011	0.032
TFPIβ	rs2192825^b	Intronic	T:C	0.466	−0.251	−0.249	0.002	0.012
TFPIβ	rs7594359^b	Intronic	C:T	0.483	−0.248	−0.247	0.002	0.012
TFPIα + β	rs2192824^b	Intronic	C:T	0.490	−0.168	−0.161	0.050	0.187
TFPIα + β	rs12613071^b	Intronic	T:C	0.158	0.238	0.164	0.048	0.187
TFPIα + β	rs7594359^b	Intronic	C:T	0.483	−0.190	−0.178	0.030	0.187

^aMajor:minor. ^bSNPs representing a haplotype effect. mRNA expression was assayed by the Agilent Human V2 Gene Expression 8x60k array, and probes for tissue factor pathway inhibitor (TFPI)α, TFPIβ and total TFPI (TFPIα + β) mRNA were analyzed. Alleles for the positive DNA strand (UCSC annotated) are shown, and SNPs are listed by ascending chromosome positions.